<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01261234</url>
  </required_header>
  <id_info>
    <org_study_id>TRIBRAIN1010</org_study_id>
    <secondary_id>UMIN000004705</secondary_id>
    <nct_id>NCT01261234</nct_id>
  </id_info>
  <brief_title>Carotid Artery Stenting With Cilostazol Addition for Restenosis</brief_title>
  <acronym>CAS-CARE</acronym>
  <official_title>Effect of Cilostazol on In-stent Restenosis After Carotid Artery Stenting; Multi-center, Prospective, Randomized, Open-label Blind-endpoint Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kobe City General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiba University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nagoya University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wakayama Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyoto University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Osaka University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kobe University</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Foundation for Biomedical Research and Innovation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Okayama University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yamaguchi University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fukuoka University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nagasaki University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kobe City General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CAS-CARE study was conducted to evaluate the inhibitory effect of cilostazol, compared to
      that of other antiplatelet drugs, on in-stent restenosis following carotid artery stenting
      (CAS) in patients scheduled to undergo CAS. Study design is Multicenter Prospective
      Ranodomized Controlled Study, rondomized by cilostazol/non-cilostazol group prior to CAS. 900
      patients will be enrolled for 2 years and followed 2 years with in-stent restenosis after
      CAS, evaluated by carotid ultrasound and angiography.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Restenosis after carotid artery stenting (CAS) is a critical issue. Cilostazol can reduce
      restenosis after interventions in coronary or femoropopliteal arteries. The investigators
      confirmed and published periprocedural cilostazol administration reduced incidences of
      in-stent restenosis (ISR) or target vessel revascularization (TVR) after CAS,
      retrospectively.

      CAS-CARE study is Multicenter Prospective Ranodomized Controlled Study. Patients, scheduled
      for CAS within 30 days, 50% or more symptomatic carotid stenosis or 80% or more asymptomatic
      carotid stenosis, will enroll and randomize by cilostazol/non-cilostazol group. 900 patients
      will be enrolled for 2 years and followed 2 years with in-stent restenosis after CAS,
      evaluated by carotid ultrasound and angiography. And, evaluate cardiovascular events,
      including stroke, myocardial infarction, and hemorrhagic events in periprocedural period and
      followed period. In this study, ISR is diagnosed by ultrasound and DSA/CTA. Equivalence of
      CTA to ultrasound will be studied.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2010</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence or absence of in-stent restenosis within 2 years after CAS and time to occurrence</measure>
    <time_frame>2 years</time_frame>
    <description>Difinition of endpoint is 50% or more in-stent restenosis detected by carotid ultrasound or angiopraphy. In cases restenosis does not occur, the final observation point will be used as the final evaluation point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular event, death, hemorrhagic event, in-stent restenosis, new out-stent stenosis, or retreatment of stented artery within 2 yrs</measure>
    <time_frame>2 years</time_frame>
    <description>Any events, including death, cardiovascular event(stroke, myocardial infarction), hemorrhagic event, in-stent restenosis, new out-stent stenosis, retreatment of stented artery, within 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent restenosis, new out-stent stenosis, or retreatment within 2 years</measure>
    <time_frame>2 years</time_frame>
    <description>In-stent restenosis, new out-stent stenosis detected by ultrasound or CTA/DSA, or retreatment of stented artery within 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemorrhagic event within 2 years</measure>
    <time_frame>2 years</time_frame>
    <description>hemorrhagic stroke, major hemorrhage required 2 unit or more transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke within 2 years</measure>
    <time_frame>2 years</time_frame>
    <description>any ischemic or hemorrhagic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent restenosis, new out-stent stenosis, or retreatment of stented artery, cardiovascular event, or death from any cause within 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Any peri-procedural events; in-stent restenosis, new out-stent stenosis, or retreatment of stented artery, cardiovascular event(stroke, myocardial infarction), or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe in-stent restenosis within 2 yrs</measure>
    <time_frame>2 yeras</time_frame>
    <description>70% or more in-stent restenosis, diagnosed by ultrasound or DSA/CTA,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in max-IMT in both common carotid arteries</measure>
    <time_frame>2 years</time_frame>
    <description>Intima-Media thickness of common carotid artery measured by ultrasound</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>In-stent Restenosis After Carotid Artery Stenting</condition>
  <arm_group>
    <arm_group_label>Cilostazol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous administration of cilostazol (unrestricted use of other antiplatelet agents and concomitant drugs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Cilostazol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antiplatelet agent other than cilostazol (unrestricted use of concomitant drugs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol or Non-Cilostazol</intervention_name>
    <description>Cilostazol group administrate 100-200mg/day per oral, unrestricted use of other antiplatelet agents and concomitant drugs.</description>
    <arm_group_label>Cilostazol group</arm_group_label>
    <arm_group_label>Non-Cilostazol group</arm_group_label>
    <other_name>Cilostazol (Pretal) group</other_name>
    <other_name>Non-Cilostazol (Pretal) group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  50% or more symptomatic carotid artery stenosis or 80% or more asymptomatic carotid
             artery stenosis

          -  scheduled for carotid artery stenting within 30 days

          -  45 or more years-old and less than 80 years old

          -  antiplatelet agents can be administratered orally

          -  follow-up is anticipated possible for 2 years after CAS

          -  self-supporoted in daily activities (modified Rankin Scale 2 or less)

          -  patients who have given informed consent to participation in the study

        Exclusion Criteria:

          -  received endovascular interevention

          -  scheduled for bilateral carotid intervention

          -  aortitis or cvasculitis

          -  congessive heart failure

          -  ischemic stroke within 48 hours

          -  hemorrhagic stroke within 90 days

          -  renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nobuyuki Sakai, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kobe City Medical Center General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hiroshi Yamagami, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kobe City Medical Center General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2010</study_first_submitted>
  <study_first_submitted_qc>December 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2010</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kobe City General Hospital</investigator_affiliation>
    <investigator_full_name>Nobuyuki Sakai</investigator_full_name>
    <investigator_title>Director, Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>Carotid Artery Disease</keyword>
  <keyword>Carotid Artery Stenting</keyword>
  <keyword>In stent restenosis</keyword>
  <keyword>Cardiovascular event</keyword>
  <keyword>Intima Media Thickness</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

